• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24117 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     National Institute for Health and Care Excellence (NICE) Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025     National Institute for Health and Care Excellence (NICE) Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025     National Institute for Health and Care Excellence (NICE) Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Prevention of hypersensitivity reactions to intravascular contrast media during medical imaging in adults]
2025     NIHR Health Services and Delivery Research programme Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025     HTA South [Vaporization with green laser for benign prostatic hyperplasia: a systematic review and assessment of medical, economic, ethical and organisational aspects]
2025     HTA South [Observation after mild head injury in patients on anticoagulation therapy: a systematic review and assessment of medical, economical and ethical aspects]
2025     Canary Health Service [Tumor treating fields (TTFields) therapy in people with newly diagnosed glioblastoma]
2025     Canary Health Service [FT-Raman spectroscopy with data analysis using machine learning for the diagnosis of platinum-resistant ovarian cancer]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (eosinophilic granulomatosis with polyangiitis) – 2nd Addendum to Project A24-113]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (eosinophilic granulomatosis with polyangiitis) – Addendum to Project A24-113]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma) – Addendum to Project A24-116]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Addendum to Project A24-110]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nemolizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nemolizumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (fibrosing interstitial lung diseases, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (systemic sclerosis associated interstitial lung disease, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipavibart (pre exposure prophylaxis of COVID 19) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pirtobrutinib (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabotegravir (HIV-1 infection in adolescents) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma, first line, combination with bortezomib, lenalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (diffuse large B-cell lymphoma [DLBCL]) – Addendum to Project A24-108]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (sickle cell disease) – Assessment according to §35a (para. 1, sentence 11) Social Code]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion dependent beta thalassaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy, 1 to 3 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CRP apheresis in acute anterior myocardial infarction Addendum to project E22-11]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Phonocardiography to rule out coronary heart disease (Addendum to Project E19-09)]
2025     Andalusian Health Technology Assessment Area (AETSA) [Impact of multidisciplinary hospital teams employing ultrasound-guided vascular access]
2025     NIHR Health Services and Delivery Research programme Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025     NIHR Health Technology Assessment programme Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025     NIHR Health Technology Assessment programme Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025     NIHR Health Services and Delivery Research programme Implementing routine assessment of perinatal anxiety: case studies
2025     NIHR Health Services and Delivery Research programme How to implement digital clinical consultations in UK maternity care: the ARM@DA Realist Review
2025     Health Information and Quality Authority (HIQA) Evidence review of specialist cardiac services
2025     Agency for Care Effectiveness (ACE) Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025     Agency for Care Effectiveness (ACE) Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025     Agency for Care Effectiveness (ACE) Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025     Agency for Care Effectiveness (ACE) Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025     NIHR Health Technology Assessment programme Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025     NIHR Health Technology Assessment programme Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025     NIHR Health Technology Assessment programme Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025     NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
2025     National Institute for Health and Care Excellence (NICE) Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025     National Institute for Health and Care Excellence (NICE) Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Algorithm for the management of low back pain with or without radicular pain]
2025     Agency for Care Effectiveness (ACE) Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025     Agency for Care Effectiveness (ACE) Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025     Agency for Care Effectiveness (ACE) Antibacterial envelope for implantable neurostimulator infection control
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025     NIHR Health Technology Assessment programme Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Non-pharmacological interventions, other than psychosocial ones, for youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Pharmacological treatment of migraine]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding vitamin-dependent rickets screening to neonatal screening]
2025     Technology Assessment at SickKids (TASK) A microcosting and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025     Agency for Care Effectiveness (ACE) EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025     Agency for Care Effectiveness (ACE) Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025     NIHR Health Technology Assessment programme High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs
2025     National Institute for Health and Care Excellence (NICE) Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour. NICE interventional procedures guidance 800
2025     National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2025     National Institute for Health and Care Excellence (NICE) Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. NICE technology appraisal guidance 1051
2025     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over. NICE technology appraisal guidance 1054
2025     National Institute for Health and Care Excellence (NICE) Cladribine for treating active relapsing forms of multiple sclerosis. NICE technology appraisal guidance 1053
2025     National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone for treating symptoms of endometriosis. NICE technology appraisal guidance 1057
2025     National Institute for Health and Care Excellence (NICE) Molnupiravir for treating COVID-19. NICE technology appraisal guidance 1056
2025     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1055
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025     NIHR Health and Social Care Delivery Program Opportunities and practices supporting responsive health care for forced migrants: lessons from transnational practice and a mixed-methods systematic review
2025     NIHR Health and Social Care Delivery Program Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: a realist review
2025     NIHR Health Technology Assessment programme A network approach to addressing the needs of patients with incurable head and neck cancer and their families
2025     NIHR Health and Social Care Delivery Program The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment
2025     Penn Medicine Center for Evidence-based Practice (CEP) Alpha-blocking medication before removal of indwelling urinary catheters
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Hospital at home in Québec healthcare institutions: considerations to support program implementation]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [New drug treatments for Alzheimer's disease: considerations for patient management]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of mitral insufficiency with a percutaneous device with clip (TEER) in Quebec - characteristics, continuum of care and clinical outcomes of adult clientele treated between 2019-2020 and 2021-2022]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of bladder cancer patients]
2025     NIHR Health and Social Care Delivery Program Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025     NIHR Health and Social Care Delivery Program Organising general practice for care homes: a multi-method study
2025     HTA South [Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025     NIHR Health and Social Care Delivery Program Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025     NIHR Health and Social Care Delivery Program Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025     NIHR Health Technology Assessment programme Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial